NZ590861A - 5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activities - Google Patents
5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activitiesInfo
- Publication number
- NZ590861A NZ590861A NZ590861A NZ59086109A NZ590861A NZ 590861 A NZ590861 A NZ 590861A NZ 590861 A NZ590861 A NZ 590861A NZ 59086109 A NZ59086109 A NZ 59086109A NZ 590861 A NZ590861 A NZ 590861A
- Authority
- NZ
- New Zealand
- Prior art keywords
- phenyl
- isoxazole
- dihydroxy
- disease
- carboxylic acid
- Prior art date
Links
- ASVXNFGUPSDDTA-UHFFFAOYSA-N 5-phenyl-1,2-oxazole-3-carboxamide Chemical class O1N=C(C(=O)N)C=C1C1=CC=CC=C1 ASVXNFGUPSDDTA-UHFFFAOYSA-N 0.000 title 1
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 title 1
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 title 1
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- HAMKBSLGCXVDLO-UHFFFAOYSA-N 4-[[4-(aminomethyl)cyclohexanecarbonyl]amino]-5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1NC(=O)C1CCC(CN)CC1 HAMKBSLGCXVDLO-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102100032187 Androgen receptor Human genes 0.000 abstract 1
- 102000014461 Ataxins Human genes 0.000 abstract 1
- 108010078286 Ataxins Proteins 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008025 Cerebellar ataxia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 abstract 1
- 101710113864 Heat shock protein 90 Proteins 0.000 abstract 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 abstract 1
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 abstract 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 108010006519 Molecular Chaperones Proteins 0.000 abstract 1
- 102000005431 Molecular Chaperones Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000009182 Parasitemia Diseases 0.000 abstract 1
- 208000030852 Parasitic disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 abstract 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- -1 aryl isoxazole derivatives Chemical class 0.000 abstract 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- WEAJPAPZLYQPRZ-UHFFFAOYSA-N chembl1940918 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1NC(C)=O WEAJPAPZLYQPRZ-UHFFFAOYSA-N 0.000 abstract 1
- NRDHRUUAIBGJLZ-UHFFFAOYSA-N chembl1940919 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1NC(=O)C(C)(C)C NRDHRUUAIBGJLZ-UHFFFAOYSA-N 0.000 abstract 1
- RKZLDDWBCRFJFY-UHFFFAOYSA-N chembl1941073 Chemical compound C=1C=C2C=CNC2=CC=1C(=O)NC=1C(C(=O)NCC)=NOC=1C1=CC(C(C)C)=C(O)C=C1O RKZLDDWBCRFJFY-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08159692 | 2008-07-04 | ||
| PCT/EP2009/058205 WO2010000748A1 (en) | 2008-07-04 | 2009-06-30 | 5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ590861A true NZ590861A (en) | 2012-08-31 |
Family
ID=40019071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ590861A NZ590861A (en) | 2008-07-04 | 2009-06-30 | 5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activities |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8383616B2 (enExample) |
| EP (1) | EP2310377B1 (enExample) |
| JP (1) | JP5640002B2 (enExample) |
| KR (1) | KR20110050615A (enExample) |
| CN (1) | CN102083804A (enExample) |
| AR (1) | AR072793A1 (enExample) |
| AU (1) | AU2009265745B2 (enExample) |
| BR (1) | BRPI0913834A2 (enExample) |
| CA (1) | CA2729710A1 (enExample) |
| EA (1) | EA019793B1 (enExample) |
| IL (1) | IL210200A0 (enExample) |
| MX (1) | MX2010013913A (enExample) |
| MY (1) | MY150604A (enExample) |
| NZ (1) | NZ590861A (enExample) |
| SG (1) | SG192464A1 (enExample) |
| TW (1) | TWI450898B (enExample) |
| WO (1) | WO2010000748A1 (enExample) |
| ZA (1) | ZA201100007B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236838B2 (en) * | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
| US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
| EP3190083B1 (en) | 2010-10-27 | 2020-08-26 | Pixelligent Technologies, LLC | Synthesis, capping and dispersion of nanocrystals |
| KR101275264B1 (ko) * | 2011-08-24 | 2013-06-17 | 포항공과대학교 산학협력단 | 샤프로닌 단백질의 조절 물질 탐색 방법 |
| CN103724269B (zh) * | 2012-10-11 | 2016-12-21 | 中国科学院上海药物研究所 | 苯基1,2-异噁唑或苯基1,2-吡唑类化合物及其用途 |
| WO2015143004A1 (en) * | 2014-03-18 | 2015-09-24 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| US9855249B2 (en) | 2014-10-02 | 2018-01-02 | Flatley Discovery Lab, Llc | Isoxazole compounds and methods for the treatment of cystic fibrosis |
| CA2972239A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN104725329B (zh) * | 2015-01-13 | 2017-01-18 | 陕西科技大学 | 一种具有抗肿瘤活性的异恶唑羧酸类化合物及其合成方法 |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| CN104803934B (zh) * | 2015-05-04 | 2018-01-02 | 陕西科技大学 | 一种具有抗肿瘤活性的苯基异噁唑羧酸类化合物及其合成方法与应用 |
| IT201700081419A1 (it) * | 2017-07-18 | 2019-01-18 | Rare Partners Srl | Derivati isossazolici come induttori di emoglobina fetale in precursori eritroidi derivati da pazienti beta-talassemici |
| JP7590185B2 (ja) * | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| CN117105880B (zh) * | 2022-10-17 | 2025-08-26 | 上海康斯维克生物医药有限公司 | 用作诱发抗原特异性反应的脲类化合物、其荧光标记物及制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1258484B1 (en) * | 2000-02-18 | 2009-01-14 | Kyowa Hakko Kirin Co., Ltd. | Novel isoxazole and thiazole compounds and use thereof as drugs |
| US7705027B2 (en) * | 2003-02-11 | 2010-04-27 | Vernalis (Cambridge) Limited | Isoxazole compounds as inhibitors of heat shock proteins |
| KR101394245B1 (ko) * | 2005-12-30 | 2014-05-14 | 에스케이바이오팜 주식회사 | 아이속사졸 유도체 및 이의 용도 |
| GB0603880D0 (en) * | 2006-02-27 | 2006-04-05 | Novartis Ag | Organic compounds |
| PL2131845T3 (pl) * | 2007-03-01 | 2012-09-28 | Novartis Ag | Metanosulfonian etyloamidu kwasu 5-(2,4-dihydroksy-5-izopropylo-fenylo)-4-(4-morfolin-4-ylometylofenylo)-izoksazolo-3-karboksylowego, jego hydraty i polimorfy, oraz preparaty zawierające te postacie |
-
2009
- 2009-06-17 TW TW098120258A patent/TWI450898B/zh not_active IP Right Cessation
- 2009-06-30 US US13/001,652 patent/US8383616B2/en not_active Expired - Fee Related
- 2009-06-30 MX MX2010013913A patent/MX2010013913A/es active IP Right Grant
- 2009-06-30 AU AU2009265745A patent/AU2009265745B2/en not_active Ceased
- 2009-06-30 WO PCT/EP2009/058205 patent/WO2010000748A1/en not_active Ceased
- 2009-06-30 EP EP09772448.8A patent/EP2310377B1/en not_active Not-in-force
- 2009-06-30 CA CA2729710A patent/CA2729710A1/en not_active Abandoned
- 2009-06-30 SG SG2013051305A patent/SG192464A1/en unknown
- 2009-06-30 JP JP2011515438A patent/JP5640002B2/ja not_active Expired - Fee Related
- 2009-06-30 BR BRPI0913834A patent/BRPI0913834A2/pt not_active IP Right Cessation
- 2009-06-30 KR KR1020117000312A patent/KR20110050615A/ko not_active Ceased
- 2009-06-30 NZ NZ590861A patent/NZ590861A/xx not_active IP Right Cessation
- 2009-06-30 MY MYPI20105887 patent/MY150604A/en unknown
- 2009-06-30 EA EA201170139A patent/EA019793B1/ru not_active IP Right Cessation
- 2009-06-30 CN CN2009801255931A patent/CN102083804A/zh active Pending
- 2009-07-03 AR ARP090102496A patent/AR072793A1/es unknown
-
2010
- 2010-12-23 IL IL210200A patent/IL210200A0/en unknown
-
2011
- 2011-01-03 ZA ZA2011/00007A patent/ZA201100007B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL210200A0 (en) | 2011-03-31 |
| US20110245221A1 (en) | 2011-10-06 |
| EP2310377A1 (en) | 2011-04-20 |
| AU2009265745A1 (en) | 2010-01-07 |
| AU2009265745B2 (en) | 2013-07-04 |
| JP2011526594A (ja) | 2011-10-13 |
| MX2010013913A (es) | 2011-03-03 |
| TWI450898B (zh) | 2014-09-01 |
| MY150604A (en) | 2014-01-30 |
| ZA201100007B (en) | 2011-10-26 |
| KR20110050615A (ko) | 2011-05-16 |
| TW201012815A (en) | 2010-04-01 |
| US8383616B2 (en) | 2013-02-26 |
| WO2010000748A1 (en) | 2010-01-07 |
| JP5640002B2 (ja) | 2014-12-10 |
| CN102083804A (zh) | 2011-06-01 |
| AR072793A1 (es) | 2010-09-22 |
| CA2729710A1 (en) | 2010-01-07 |
| BRPI0913834A2 (pt) | 2015-10-20 |
| SG192464A1 (en) | 2013-08-30 |
| EA201170139A1 (ru) | 2011-08-30 |
| EA019793B1 (ru) | 2014-06-30 |
| EP2310377B1 (en) | 2015-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ590861A (en) | 5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activities | |
| PH12019501707A1 (en) | N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor | |
| JOP20200042A1 (ar) | مشتقات 3-(1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6-دايون واستخداماتها | |
| PE20080972A1 (es) | Inhibidores de rho cinasa | |
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
| IL189762A0 (en) | Isoxazolo derivatives as gaba a alpha5 inverse agonists | |
| NZ596579A (en) | Bace inhibitors | |
| NO20083598L (no) | Karbosykliske og heterosykliske arylsulfoner som inhibitorer av gamma-sekretase | |
| MX2009011830A (es) | Compuestos amino-heterociclicos. | |
| DE602004028150D1 (de) | Aminopyrazolderivate als gsk-3-inhibitoren | |
| NO20084516L (no) | Terfenylderivater for behandling av alzheimers sykdom | |
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| PE20091005A1 (es) | N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas | |
| EP1740559A4 (en) | ALSHEETS INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE SUITABLE 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS | |
| WO2005011601A3 (en) | 6-menbered heteroaryl compounds for the treatment of neurodegenerative disorders | |
| CY1118623T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινων ως αναστολεις της bace | |
| CY1119787T1 (el) | Υποκατεστημενα παραγωγα 2-[2-(φαινυλ)αιθυλαμινο] αλκαναμιδιου και η χρηση αυτων ως τροποποιητων του διαυλου νατριου και/ή ασβεστιου | |
| CY1110343T1 (el) | 2-(πυριδιν-2-υλο)-πυριμιδινες και η χρησιμοποιηση του για την καταπολεμηση επιζημιων μυκητων | |
| SI3102573T1 (en) | SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7 | |
| ATE535241T1 (de) | Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämie | |
| MX2010002766A (es) | 3-metil-2-((2s)-2-(4-(3-metil-l, 2, 4-oxadiazol-5-il-) fenil) morfolino) -6- (pirimidin-4-il) pirimidin-4 (3h) -ona como inhibidor de tau proteina cinasa. | |
| IL205045A (en) | Piperidinyl and piperazine derivatives, preparations containing them and their uses | |
| IL200401A0 (en) | Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms | |
| NO20071319L (no) | Fremgangsmate for fremstilling av isotiazolderivater. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 JUN 2016 BY COMPUTER PACKAGES INC Effective date: 20130709 |
|
| LAPS | Patent lapsed |